These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

700 related articles for article (PubMed ID: 22481232)

  • 21. Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer.
    Rivera MP; Detterbeck FC; Socinski MA; Moore DT; Edelman MJ; Jahan TM; Ansari RH; Luketich JD; Peng G; Monberg M; Obasaju CK; Gralla RJ
    Chest; 2009 Jun; 135(6):1588-1595. PubMed ID: 19188545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
    Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
    Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low expression of Bax predicts poor prognosis in resected non-small cell lung cancer patients with non-squamous histology.
    Jeong SH; Lee HW; Han JH; Kang SY; Choi JH; Jung YM; Choi H; Oh YT; Park KJ; Hwang SC; Sheen SS; Oh YJ; Kim JH; Lim HY
    Jpn J Clin Oncol; 2008 Oct; 38(10):661-9. PubMed ID: 18772168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
    Xiong L; Cheng J; Gao J; Wang J; Liu X; Wang L
    Clin Lung Cancer; 2013 Jul; 14(4):433-9. PubMed ID: 23522953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center.
    Zhu J; Zhang Y; Wang M; Zhang Z; Yue D; Liu S; Pan Y; Wang C
    Med Sci Monit; 2021 Aug; 27():e930738. PubMed ID: 34376631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant chemotherapy followed by surgery in lung cancer: Indian scenario.
    Kumar S; Saikia J; Kumar V; Malik PS; Madan K; Jain D; Bharati S
    Curr Probl Cancer; 2020 Jun; 44(3):100563. PubMed ID: 32265058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer.
    Uramoto H; Nakanishi R; Nagashima A; Uchiyama A; Inoue M; Osaki T; Yoshimatsu T; Sakata H; Nakanishi K; Yasumoto K
    Anticancer Res; 2010 Nov; 30(11):4695-9. PubMed ID: 21115926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials.
    Mouillet G; Monnet E; Milleron B; Puyraveau M; Quoix E; David P; Ducoloné A; Molinier O; Zalcman G; Depierre A; Westeel V;
    J Thorac Oncol; 2012 May; 7(5):841-9. PubMed ID: 22722786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy.
    Najjar F; Alammar M; Bachour M; Almalla N; Altahan M; Alali A; Al-Massarani G
    J Cancer Res Clin Oncol; 2015 Jan; 141(1):119-25. PubMed ID: 25037116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy.
    Najjar F; Al-Massarani G; Banat I; Alammar M
    Int J Biol Markers; 2015 Nov; 30(4):e374-81. PubMed ID: 26109363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors Associated With Survival in Complete Pathologic Response Non-Small Cell Lung Cancer.
    Martinez-Meehan D; Lutfi W; Dhupar R; Christie N; Baker N; Schuchert M; Luketich JD; Okusanya OT
    Clin Lung Cancer; 2020 Jul; 21(4):349-356. PubMed ID: 32299769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
    Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis.
    Hansen RN; Zhang Y; Seal B; Ryan K; Yong C; Darilay A; Ramsey SD
    BMC Cancer; 2020 Apr; 20(1):276. PubMed ID: 32248816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of Elderly Patients Who Receive Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer.
    Zaki M; Dominello M; Dyson G; Gadgeel S; Wozniak A; Miller S; Paximadis P
    Clin Lung Cancer; 2017 Jan; 18(1):e21-e26. PubMed ID: 27567356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long term follow-up of neoadjuvant-adjuvant combination treatment of IIIA stage non-small-cell-lung cancer: results of neoadjuvant carboplatin/vinorelbine and carboplatin/paclitaxel regimens combined with selective adjuvant chemotherapy according to in-vitro chemoresistance test.
    Kolek V; Grygarkova I; Hajduch M; Klein J; Cwiertka K; Neoral C; Langova K; Mihal V
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2008 Dec; 152(2):259-66. PubMed ID: 19219217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer.
    Li CH; Liu MY; Liu W; Li DD; Cai L
    Asian Pac J Cancer Prev; 2014; 15(2):731-6. PubMed ID: 24568487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer.
    Zhang J; Gay HA; Russo S; Parent T; Aljumaily R; Walker PR
    Lung Cancer; 2014 Jan; 83(1):67-72. PubMed ID: 24246506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma.
    Gakis G; Morgan TM; Daneshmand S; Keegan KA; Todenhöfer T; Mischinger J; Schubert T; Zaid HB; Hrbacek J; Ali-El-Dein B; Clayman RH; Galland S; Olugbade K; Rink M; Fritsche HM; Burger M; Chang SS; Babjuk M; Thalmann GN; Stenzl A; Efstathiou JA
    Ann Oncol; 2015 Aug; 26(8):1754-9. PubMed ID: 25969370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
    Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
    Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.